Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly
|
| gptkbp:country |
gptkb:China
|
| gptkbp:developed_COVID-19_antibody_therapy |
etesevimab
|
| gptkbp:focus |
immuno-oncology
autoimmune diseases |
| gptkbp:founded |
2012
|
| gptkbp:headquarters_location |
gptkb:Shanghai
|
| gptkbp:industry |
biopharmaceuticals
|
| gptkbp:notableProduct |
gptkb:toripalimab
|
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:1877.HK
|
| gptkbp:toripalimab_is |
PD-1 inhibitor
|
| gptkbp:website |
https://www.junshipharma.com/en/
|
| gptkbp:bfsParent |
gptkb:WuXi_Biologics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Junshi Biosciences
|